Filter Results
:
(1,001)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for...
View Details
Keywords:
Research and Development;
Intellectual Property;
Risk and Uncertainty;
Strategic Planning;
Collaborative Innovation and Invention;
Health Disorders;
Pharmaceutical Industry;
Biotechnology Industry;
Health Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- March 2006 (Revised July 2006)
- Supplement
Drug Testing in Nigeria (B)
By: Debora L. Spar
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (B)." Harvard Business School Supplement 706-042, March 2006. (Revised July 2006.)
- Research Summary
FDA Review Time of New Drug Applications
Study of FDA Review Time of New Drug Applications (NDAs) between 1990-2004. Three main questions are addressed: How the optimal innovation strategy for firms is contingent upon firm status positions in the knowledge domain; how knowledge status both enables and...
View Details
- January 2015 (Revised July 2019)
- Case
CVS Health: Promoting Drug Adherence
Email mking@hbs.edu for a courtesy copy.
The case describes a program that CVS Health recently implemented to improve medication adherence, an important problem from a societal, public policy, and firm... View Details
The case describes a program that CVS Health recently implemented to improve medication adherence, an important problem from a societal, public policy, and firm... View Details
Keywords:
Medication Adherence;
Affordable Care Act (ACA);
Marketing Strategy;
Communication Strategy;
Customer Value and Value Chain;
Decisions;
Health Care and Treatment;
Goals and Objectives;
Resource Allocation;
Marketing Communications;
Consumer Behavior;
Measurement and Metrics;
Service Delivery;
Behavior;
Motivation and Incentives;
Social Issues;
Information Technology;
Value Creation;
Health Industry;
Pharmaceutical Industry;
Insurance Industry;
Public Relations Industry;
Retail Industry;
United States
John, Leslie, John Quelch, and Robert Huckman. "CVS Health: Promoting Drug Adherence." Harvard Business School Case 515-010, January 2015. (Revised July 2019.) (Email mking@hbs.edu for a courtesy copy.)
- April 1989 (Revised July 1992)
- Supplement
Technology Transfer: Anti-Inflammatory Drug (C)
Herzlinger, Regina E. "Technology Transfer: Anti-Inflammatory Drug (C)." Harvard Business School Supplement 189-167, April 1989. (Revised July 1992.)
- May 2005
- Supplement
GlaxoSmithKline: Reorganizing Drug Discovery (B)
By: Robert S. Huckman and Eli Strick
Supplements the (A) case.
View Details
Keywords:
Mergers and Acquisitions;
Decisions;
Operations;
Performance;
Research and Development;
Restructuring;
Organizations;
Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (B)." Harvard Business School Supplement 605-075, May 2005.
- Web
Drug & Alcohol Policy | About
Drug & Alcohol Policy Overview of HBS Substance Abuse Policies and Procedures Harvard Business School’s policy on drugs and alcohol—adapted from and in accordance with other similar policies at Harvard...
View Details
- February 1998 (Revised October 1998)
- Background Note
Note on New Drug Development in the United States
By: Stefan H. Thomke and Ashok Nimgade
An overview of the new drug development process in the United States, using the migraine drug Imitrex as an illustrative example.
View Details
Keywords:
Product Development;
Research and Development;
Health;
Pharmaceutical Industry;
United States
Thomke, Stefan H., and Ashok Nimgade. "Note on New Drug Development in the United States." Harvard Business School Background Note 698-028, February 1998. (Revised October 1998.)
- Article
Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study
By: Noy Alon, Ariel Dora Stern and John Torous
BACKGROUND: As the development of mobile health apps continues to accelerate, the need to implement a framework that can standardize categorizing these apps to allow for efficient, yet robust regulation grows. However, regulators and researchers are faced with numerous...
View Details
Keywords:
Mobile Health;
Smartphone;
Food And Drug Administration;
Risk-based Framework;
Health Care and Treatment;
Mobile and Wireless Technology;
Applications and Software;
Framework
Alon, Noy, Ariel Dora Stern, and John Torous. "Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study." JMIR mHealth and uHealth 8, no. 10 (October 2020).
- 14 Nov 2019
- Video
Health Minute: The Real Impact of Coupons on Drug Pricing
- 25 Sep 2017
- News
When a Drug Coupon Helps You but Hurts Fellow Citizens
- April 1989 (Revised July 1992)
- Supplement
Technology Transfer: Anti-Inflammatory Drug (B)
Herzlinger, Regina E. "Technology Transfer: Anti-Inflammatory Drug (B)." Harvard Business School Supplement 189-166, April 1989. (Revised July 1992.)
- 25 Nov 2015
- News
Pfizer-Allergan Merger Won't Lead to New, Innovative Drugs
- 01 Mar 2011
- News
Fixing What Ails the Drug Industry
echoed Hamburg’s call for improvements in regulation, but he also emphasized the innovation side of the balancing act between safety and product development. “Reinvent invention,” he told the audience. The industry must get smarter about developing View Details
- Web
2.3.1 Drug & Alcohol Policy - MBA
2.3 Community Standards of Conduct 2.3.1 Drug & Alcohol Policy Welcome to HBS Being a Student at HBS 1. Academic Information & Policies 2. Integrity & Standards of Conduct 2.1 Academic Standards of Conduct 2.2 Recruiting Standards of...
View Details
- 06 Sep 2022
- Research & Ideas
Curbing an Unlikely Culprit of Rising Drug Prices: Pharmaceutical Donations
Prescription drug costs continue to climb in the United States, but tightening a loophole in a federal law may help curb rising expenses, according to research published this week in Health Affairs. Efforts to control US health care...
View Details
- October 2010 (Revised November 2010)
- Background Note
Plavix: Drugs in the Age of Personalized Medicine
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even...
View Details
Keywords:
Health Care and Treatment;
Product Positioning;
Business and Government Relations;
Genetics;
Competitive Strategy;
Pharmaceutical Industry
Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
- April 1989 (Revised May 1993)
- Case
Novel Combination of Two Drugs (A)
Herzlinger, Regina E. "Novel Combination of Two Drugs (A)." Harvard Business School Case 189-168, April 1989. (Revised May 1993.)
- 11 Jun 2009
- News
Novartis: Radically Remaking Its Drug Business
- 2019
- Chapter
Characterizing the Drug Development Pipeline for Precision Medicines
By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement...
View Details
Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.